Evocalcet

Evocalcet
Clinical data
Trade namesOrkedia
ATC code
Identifiers
  • 2-[4-[(3S)-3-[[(1R)-1-Naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]acetic acid
CAS Number
PubChem CID
DrugBank
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H26N2O2
Molar mass374.484 g·mol−1

Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism.[1] It acts as a calcium-sensing receptor agonist.[2]

In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis.[3]

References

  1. ^ Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, et al. (2018). "A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro". PLOS ONE. 13 (4): e0195316. Bibcode:2018PLoSO..1395316K. doi:10.1371/journal.pone.0195316. PMC 5882164. PMID 29614098.
  2. ^ Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, et al. (June 2018). "Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism". Bioorganic & Medicinal Chemistry Letters. 28 (11): 2055–2060. doi:10.1016/j.bmcl.2018.04.055. PMID 29724589.
  3. ^ "Kyowa Hakko Kirin Launches Orkedia Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan" (Press release). Kyowa Hakko Kirin. May 22, 2018.


Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.